



Contents

4Q 2020 Earnings Summary	4~6
■ 4Q Results & Outlook by Business	7~11
■ 2021 Business Outlook	12
■ Business Review & Strategy	13~15

- Sales & Operating Profit by Business
- Income Statements / Financial Position / Cash Flows

16~20

- CAPEX & R&D Expenses

Appendix

The business results currently under audit review are presented here for investors' convenience. Hence, please be advised that some of their contents may be altered in the course of audit.


The business results are subject to the K-IFRS(Korea International Financial Reporting Standards).

Forecasts and projections contained in this material are based on current business environments and management's strategies. Please note it may differ from actual results, due to uncertainties including changes in the future business environment and recalibration of strategy.

2020 Business Results

Sales





X The historical business results retroactively excluded the results of the discounted and held for sale business.

Operating Profit(%)

		'18	'19	'20	YoY
L	.G Chem(%)	2,289	825	1,798	+117.9%
	Petro chemicals	2,032	1,417	1,968	+38.9%
	Advanced Materials	(12.0%) 52 (2.0%)	(9.1%) 7 (0.2%)	(13.8%) 163 (4.5%)	+2,227.1%
	Life Sciences	50	(5.9%)	(4.5%) 54 (8.1%)	+44.6%
	Energy Solution	(8.6%)	-454 (-5.4%)	-167 (-1.3%)	
	Farm Hannong	15 (2.6%)	(3.5%)	25 (4.1%)	+18.2%
ı	EBITDA(%)	3,773 (14.1%)	2,684 (9.8%)	4,110 (13.7%)	+53.1%

4Q 2020 Business Results

			2019					2020			V-V	0.0
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	YoY	QoQ
Sales	6,265	6,778	6,899	7,411	27,353	6,729	6,935	7,507	8,905	30,077	+20.2%	+18.6%
ОР	263	247	349	-33	825	206	572	902	119	1,798	Turn	-86.9%
(%)	4.2%	3.6%	5.1%	-0.5%	3.0%	3.1%	8.2%	12.0%	1.3%	6.0%	a profit	-00.9%
EBITDA	670	702	830	483	2,684	736	1,130	1,490	755	4,110	+56.4%	-49.4%
(%)	10.7%	10.4%	12.0%	6.5%	9.8%	10.9%	16.3%	19.9%	8.5%	13.7%	T30.4 /6	-43.476
Pre-tax Income	261	187	223	-97	574	158	470	708	-392	944	_	Turn
(%)	4.2%	2.8%	3.2%	-1.3%	2.1%	2.3%	6.8%	9.4%	-4.4%	3.1%	-	a loss
Net Income	212	84	137	-57	376	36	419	570	-343	682		Turn
(%)	3.4%	1.2%	2.0%	-0.8%	1.4%	0.5%	6.0%	7.6%	-3.9%	2.3%	•	a loss

X The historical business results retroactively excluded the results of the discounted and held for sale business.

4Q 2020 Business Results

Balance Sheet


Financial Ratios

	4Q 2019	3Q 2020	4Q 2020
Asset	34.0	40.0	41.4
Cash and Equivalents	1.9	3.6	3.9
Liabilities	16.6	21.2	22.6
Debt	8.4	11.4	10.2
Shareholder's Equity	17.4	18.8	18.8

	4Q 2019	3Q 2020	4Q 2020
Liabilities / Equity	95.7%	112.6%	120.3%
Debts / Equity	48.4%	60.4%	54.2%
Net Debts / Equity	37.4%	41.5%	33.5%
ROE	2.2%	12.4%	3.8%
ROA	1.2%	5.8%	1.8%

[※] ROE: Net Income / Avg of beginning & ending shareholders' equity ROA: Net Income / Avg of beginning & ending assets

Petrochemicals




[Analysis]

 Despite the impact from Yeosu NCC ESD and FX, robust profitability from improved spread of key products

[Outlook]

 Although supply increases in Upstream by new capacity expansions, demand is expected to be recovered

4Q Results & Outlook by Business Advanced Materials




[Analysis]

 While sales grew from increased shipments of battery materials, profitability declined due to the FX

[Outlook]

 While the negative FX impact to continue, expect sales and profitability to improve centered around battery materials

Life Sciences




[Analysis]

 Solid sales and profitability due to strong sales of Zemiglo and Yvoire

[Outlook]

 Expect sales to increase due to the launch of new products including Eupolio (polio vaccine) and strengthen new drug portfolio through expanding R&D investment

Energy Solution




[Analysis]

- Sales growth driven by increased shipment to major customers in Europe and America
- Despite profitability improvements from improved yield and reduction in fixed costs, profit decreased due to the negative FX impact and one-off cost

[Outlook]

- Expect sales to grow from greater EV sales
- Profitability improving through more efficient operation and cost improvement

Farm Hannong




[Analysis]

 YoY improvement in sales and profitability from greater sales of the seed business and improved cost structure for crop protection products

[Outlook]

 Expect growth of crop protection and seed business and sales and profitability to improve from greater sales of specialty fertilizers, etc.

2021 Business Outlook




^{**} Business outlook is based on our business plan, and may differ from actual results, due to changes in business environment and strategies. The difference between total sales and total sales by business is intra-company transactions, sales in common business, etc.

Business Review & Strategy

1 Petrochemicals






2020 Review

- Due to the spread of COVID-19, downstream's demand contracted and sales declined
- Spread widened for key products such as ABS and NBL from China's economic recovery and Mega Trend-led consumption increases
- 2021 Outlook & Strategy
 - Upstream: New & additional capa expansion in the region Downstream: demand to gradually improve from the recovery in global economic
 - Increase in demand for eco-friendly products such as solar power, EV, recycle, etc.
 - Strengthen product competitiveness, proactively review regional diversification strategy and strengthen new business development capability in promising areas related to sustainability, etc.

^{**} Business outlook is based on our business plan, and may differ from actual results, due to changes in business environment and strategies.

Business Review & Strategy

② Advanced Materials



2020 Review

- Despite weak demand from downstream due to COVID-19, sales and profitability improved in cathodes and OLED materials business
- Realigned business portfolio inc. disposal of LCD polarizer,
 Secured growth foundation by improving productivity and competitiveness of OLED materials


2021 Outlook & Strategy


- Sales growth target of more than 20% from demand growth outlook of downstream market including battery / OLED / IT
- Focus on fostering High-Ni battery material and increasing capacity
- Strengthen high-value-add products such as eco-friendly materials, light materials for e-mobility

^{**} Business outlook is based on our business plan, and may differ from actual results, due to changes in business environment and strategies.

Business Review & Strategy

3 Life Sciences





2020 Review

- Sales grew and profitability improved with the strengthening of the market status of key products such as Zemiglo (diabetes) and Eutropin (growth hormone)
- Expanded new drug development tasks and laid the foundation for global new R&D foundation by securing the pipeline through Open Innovation

2021 Outlook & Strategy

- Expect sales growth of more than 10% by supplying new product Eupolio (polio vaccine) and etc. to UNICEF and expanding existing business including Yvoire (filler)
- Increase R&D investment by strengthening global clinical and new drug portfolio

X Business outlook is based on our business plan, and may differ from actual results, due to changes in business environment and strategies.

Appendix

Sales & Operating Profits by Business

1.0.0h			2019			2020					
LG Chem	1Q	2Q	3 Q	4Q	Total	1Q	2Q	3Q	4Q	Total	
Sales	6,265	6,778	6,899	7,411	27,353	6,729	6,935	7,507	8,905	30,077	
Operating profits	263	247	349	-33	825	206	572	902	119	1,798	
(%)	4.2%	3.6%	5.1%	-0.5%	3.0%	3.1%	8.2%	12.0%	1.3%	6.0%	
EBITDA	670	702	830	483	2,684	736	1,130	1,490	755	4,110	
(%)	10.7%	10.4%	12.0%	6.5%	9.8%	10.9%	16.3%	19.9%	8.5%	13.7%	
Petrochemicals	3,749	3,936	3,965	3,898	15,548	3,696	3,313	3,584	3,676	14,269	
NCC/PO	1,136	1,270	1,327	1,316	5,048	1,261	1,077	1,140	1,155	4,634	
PVC/Plasticizer	596	538	546	545	2,225	543	467	511	529	2,050	
ABS	1,170	1,228	1,182	1,148	4,728	1,016	977	1,134	1,238	4,365	
Acrylate/SAP	447	461	479	473	1,861	484	488	475	412	1,859	
Rubber/ Specialty Polymer	400	440	431	415	1,686	391	304	323	342	1,360	
Operating Profits	397	382	321	316	1,417	243	435	722	569	1,968	
(%)	10.6%	9.7%	8.1%	8.1%	9.1%	6.6%	13.1%	20.1%	15.5%	13.8%	
Advanced Materials	888	895	811	861	3,455	849	789	963	1,010	3,611	
Operating Profits	-6	5	5	3	7	32	35	59	37	163	
(%)	-0.7%	0.6%	0.6%	0.4%	0.2%	3.8%	4.4%	6.1%	3.6%	4.5%	
Life Sciences	144	154	166	164	628	159	160	172	170	661	
Operating Profits	12	11	16	-2	37	24	14	9	8	54	
(%)	8.2%	7.1%	9.7%	-1.0%	5.9%	14.7%	8.8%	4.9%	4.6%	8.1%	
Energy Solution	1,650	2,009	2,210	2,481	8,350	2,261	2,823	3,144	4,144	12,372	
Operating Profits	-148	-128	71	-250	-454	-52	156	169	-439	-167	
(%)	-9.0%	-6.4%	3.2%	-10.1%	-5.4%	-2.3%	5.5%	5.4%	-10.6%	-1.3%	
Farm Hannong	228	170	94	99	590	221	178	102	100	601	
Operating Profits	38	9	-11	-15	21	35	12	-10	-12	25	
(%)	16.8%	5.4%	-11.9%	-15.5%	3.5%	15.8%	6.5%	-9.6%	-11.9%	4.1%	

^{**} Applied retroactive effects of past performance based on the reorganization

X The business results currently under audit review are presented here for investors' convenience. Hence, please be advised that some of their contents may be altered in the course of audit.

Income Statements

Appendix

I C Cham			2019			2020				
LG Chem	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Sales	6,265	6,778	6,899	7,411	27,353	6,729	6,935	7,507	8,905	30,077
Cost of Sales	5,130	5,674	5,701	6,163	22,668	5,620	5,422	5,711	7,012	23,764
O D51/0/)	1,135	1,105	1,198	1,247	4,686	1,109	1,513	1,796	1,893	6,312
Gross Profit(%)	18.1%	16.3%	17.4%	16.8%	17.1%	16.5%	21.8%	23.9%	21.3%	21.0%
SG&A Expenses	872	858	849	1,281	3,860	904	942	894	1,775	4,514
O	263	247	349	-33	825	206	572	902	119	1,798
Operating Profit(%)	4.2%	3.6%	5.1%	-0.5%	3.0%	3.1%	8.2%	12.0%	1.3%	6.0%
Other non-operating income(expenses)	-2	-60	-125	-64	-251	-48	-102	-194	-510	-855
Income before tax	261	187	223	-97	574	158	470	708	-392	944
Net Income	212	84	137	-57	376	36	419	570	-343	682
EPS (Unit:KRW)					4,085					6,666

X Applied retroactive effects of past performance based on the reorganization

X The business results currently under audit review are presented here for investors' convenience. Hence, please be advised that some of their contents may be altered in the course of audit.

Appendix

Financial Position

I O Oham		20	18			2019				2020			
LG Chem	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Assets	26,416	27,399	28,419	28,944	31,212	32,436	33,531	34,024	37,121	38,576	40,019	41,389	
Cash and Equivalents	3,132	2,830	3,333	2,557	3,122	2,667	2,085	1,921	2,797	3,367	3,554	3,882	
A/R	4,709	5,146	4,949	4,381	4,616	4,738	4,575	3,738	4,663	4,908	5,393	5,298	
Inventory	3,784	3,950	4,404	4,290	4,503	4,771	4,977	5,034	5,335	4,753	4,928	5,350	
Tangible / Intangible Assets	13,366	13,936	14,074	15,845	16,938	17,993	19,471	20,800	21,702	22,017	22,528	22,847	
Liabilities	9,905	10,391	11,162	11,622	14,013	15,157	16,040	16,641	19,705	20,734	21,198	22,599	
A/P	1,999	2,156	2,541	2,166	2,434	2,549	2,467	2,380	2,550	2,261	2,859	3,459	
Short-term debts	1,593	1,903	2,037	1,613	1,630	1,432	1,744	1,356	2,431	2,860	2,509	1,549	
Long-term debts	2,643	3,211	3,262	3,708	5,275	7,049	7,211	7,058	9,123	9,001	8,856	8,637	
Shareholders' Equity	16,510	17,009	17,257	17,322	17,199	17,279	17,491	17,384	17,416	17,842	18,821	18,790	
Liabilities/Equity(%)	60.0%	61.1%	64.7%	67.1%	81.5%	87.7%	91.7%	95.7%	113.1%	116.2%	112.6%	120.3%	
Net debt/Equity(%)	6.7%	13.4%	11.4%	16.0%	22.0%	33.6%	39.3%	37.4%	50.3%	47.6%	41.5%	33.5%	
BPS (Unit:KRW)	208,363	214,535	217,500	218,227	216,308	217,445	219,413	217,230	217,238	221,857	232,070	230,440	

X The business results currently under audit review are presented here for investors' convenience. Hence, please be advised that some of their contents may be altered in the course of audit.

Cash Flows

Appendix

1 O Oh			2019					2020			
LG Chem	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	
Beginning Cash Balance	2,514	3,098	2,631	2,055	2,514	1,889	2,767	3,363	3,539	1,889	
Operating Activities	644	246	395	1,836	3,121	-97	1,716	1,987	2,235	5,841	
Operating Profits	263	247	349	-33	825	206	572	902	119	1,798	
Depreciation	407	455	481	516	1,859	530	558	588	636	2,312	
Working Capital	-181	-275	-124	693	113	-1,056	48	-62	272	-797	
Investing Activities	-1,527	-1,732	-1,360	-1,493	-6,111	-1,328	-1,144	-1,000	-1,824	-5,296	
Financing Activities	1,450	986	386	-521	2,301	2,283	44	-792	-596	938	
Borrow/Repay	1,584	1,576	474	-540	3,093	3,139	308	-496	-1,179	1,772	
Dividends	-	-484	-	-	-484	-	-154	-24	-	-178	
Ending Cash Balance	3,098	2,631	2,055	1,889	1,889	2,767	3,363	3,539	3,274	3,274	

X Applied retroactive effects of past performance based on the reorganization

X The business results currently under audit review are presented here for investors' convenience. Hence, please be advised that some of their contents may be altered in the course of audit.

Appendix

CAPEX & R&D Expenses

